These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 34341803)
1. Herd immunity induced by COVID-19 vaccination programs and suppression of epidemics caused by the SARS-CoV-2 Delta variant in China. Liu H; Zhang J; Cai J; Deng X; Peng C; Chen X; Yang J; Wu Q; Chen X; Chen Z; Zheng W; Viboud C; Zhang W; Ajelli M; Yu H medRxiv; 2021 Sep; ():. PubMed ID: 34341803 [TBL] [Abstract][Full Text] [Related]
2. Investigating vaccine-induced immunity and its effect in mitigating SARS-CoV-2 epidemics in China. Liu H; Zhang J; Cai J; Deng X; Peng C; Chen X; Yang J; Wu Q; Chen X; Chen Z; Zheng W; Viboud C; Zhang W; Ajelli M; Yu H BMC Med; 2022 Jan; 20(1):37. PubMed ID: 35094714 [TBL] [Abstract][Full Text] [Related]
3. COVID-19 pandemic dynamics in India, the SARS-CoV-2 Delta variant, and implications for vaccination. Yang W; Shaman J medRxiv; 2021 Nov; ():. PubMed ID: 34845460 [TBL] [Abstract][Full Text] [Related]
4. Modelling direct and herd protection effects of vaccination against the SARS-CoV-2 Delta variant in Australia. McBryde ES; Meehan MT; Caldwell JM; Adekunle AI; Ogunlade ST; Kuddus MA; Ragonnet R; Jayasundara P; Trauer JM; Cope RC Med J Aust; 2021 Nov; 215(9):427-432. PubMed ID: 34477236 [TBL] [Abstract][Full Text] [Related]
5. Will vaccine-derived protective immunity curtail COVID-19 variants in the US? Mancuso M; Eikenberry SE; Gumel AB Infect Dis Model; 2021; 6():1110-1134. PubMed ID: 34518808 [TBL] [Abstract][Full Text] [Related]
6. Mathematical assessment of the roles of age heterogeneity and vaccination on the dynamics and control of SARS-CoV-2. Pant B; Gumel AB Infect Dis Model; 2024 Sep; 9(3):828-874. PubMed ID: 38725431 [TBL] [Abstract][Full Text] [Related]
7. The resurgence risk of COVID-19 in China in the presence of immunity waning and ADE: A mathematical modelling study. Zhou W; Tang B; Bai Y; Shao Y; Xiao Y; Tang S Vaccine; 2022 Nov; 40(49):7141-7150. PubMed ID: 36328883 [TBL] [Abstract][Full Text] [Related]
8. Percentages of Vaccination Coverage Required to Establish Herd Immunity against SARS-CoV-2. Plans-Rubió P Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632492 [TBL] [Abstract][Full Text] [Related]
9. Impact of Microbiota: A Paradigm for Evolving Herd Immunity against Viral Diseases. Shelly A; Gupta P; Ahuja R; Srichandan S; Meena J; Majumdar T Viruses; 2020 Oct; 12(10):. PubMed ID: 33050511 [TBL] [Abstract][Full Text] [Related]
10. Network models to evaluate vaccine strategies towards herd immunity in COVID-19. Tetteh JNA; Nguyen VK; Hernandez-Vargas EA J Theor Biol; 2021 Dec; 531():110894. PubMed ID: 34508758 [TBL] [Abstract][Full Text] [Related]
11. Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants. Liu F; Zhao Z; Ma C; Nie X; Wu A; Li X Epidemiol Infect; 2022 Jan; 150():e46. PubMed ID: 35067231 [TBL] [Abstract][Full Text] [Related]
12. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P Cells; 2021 Oct; 10(11):. PubMed ID: 34831172 [TBL] [Abstract][Full Text] [Related]
13. The potential for vaccination-induced herd immunity against the SARS-CoV-2 B.1.1.7 variant. Hodgson D; Flasche S; Jit M; Kucharski AJ; ; Euro Surveill; 2021 May; 26(20):. PubMed ID: 34018481 [TBL] [Abstract][Full Text] [Related]
14. Dynamics of COVID-19 in Amazonia: A history of government denialism and the risk of a third wave. Ferrante L; Duczmal LH; Capanema E; Steinmetz WAC; Almeida ACL; Leão J; Vassão RC; Fearnside PM; Tupinambás U Prev Med Rep; 2022 Apr; 26():101752. PubMed ID: 35242505 [TBL] [Abstract][Full Text] [Related]
15. Challenges in Engendering Herd Immunity to SARS-CoV-2 Infection: Possibly Impossible But Plausibile. Mukherjee S; Ray SK Infect Disord Drug Targets; 2022; 22(4):e170122200309. PubMed ID: 35040409 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study. Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940 [TBL] [Abstract][Full Text] [Related]
17. [Review of the concept of herd immunity, in the context of COVID-19 epidemic and the development of vaccines]. Canals L M Rev Chilena Infectol; 2021 Aug; 38(4):495-499. PubMed ID: 34652394 [TBL] [Abstract][Full Text] [Related]
18. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
19. A country-specific model of COVID-19 vaccination coverage needed for herd immunity in adult only or population wide vaccination programme. Goh FT; Chew YZ; Tam CC; Yung CF; Clapham H Epidemics; 2022 Jun; 39():100581. PubMed ID: 35636311 [TBL] [Abstract][Full Text] [Related]
20. Model based estimation of the SARS-CoV-2 immunization level in austria and consequences for herd immunity effects. Bicher M; Rippinger C; Schneckenreither G; Weibrecht N; Urach C; Zechmeister M; Brunmeir D; Huf W; Popper N Sci Rep; 2022 Feb; 12(1):2872. PubMed ID: 35190590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]